<DOC>
	<DOCNO>NCT00384618</DOCNO>
	<brief_summary>The ATIC study randomise , double- blind , placebo-controlled trial effect oxidative stress-lowering treatment vascular function structure study patient chronic non-diabetic renal failure free manifest arterial occlusive disease . Participants trial randomise active treatment consist add-on therapy pravastatin , vitamin E homocysteine-lowering therapy , placebo . Subjects use angiotensin convert enzyme inhibitor ( ACE-inhibitors ) angiotensin receptor blocker ( ARBs ) inclusion put ACE-inhibitors least two week baseline measurement randomisation . Those ARBs continue ARBs . We exclude individual diabetes mellitus ( ADA criterion ) , active vasculitis , nephrotic syndrome ( &gt; 3gr/24hr urine protein ) , renal transplantation , fast total cholesterol &gt; 7 mmol/L , cholesterol-lowering therapy within three month prior inclusion know ischemic cardiac , cerebrovascular peripheral arterial disease . Ninety-three patient ( 118 eligible patient ) take part study write informed consent obtain participant .</brief_summary>
	<brief_title>Anti-Oxidant Therapy In Chronic Renal Insufficiency ( ATIC ) Study</brief_title>
	<detailed_description>Background : Patients mild-to-moderate renal failure increase risk cardiovascular disease ( CVD ) , fully explain presence classical cardiovascular risk factor . Oxidative stress propose play major role development CVD among renal failure patient . We investigate , patient mild-to-moderate chronic kidney disease ( CKD ) , effect oxidative-stress-lowering therapy pravastatin , vitamin E homocysteine-lowering carotid intima-media thickness endothelial function ( two strong surrogate marker cardiovascular risk ) , renal function . Methods : 93 patient CKD ( Cockcroft-Gault equation ; mean : 41Â±17 ml / min per 1.73 m2 ) free manifest arterial occlusive disease diabetes mellitus include Anti-oxidant Therapy In Chronic renal insufficiency ( ATIC ) study , randomize , double-blind , placebo-controlled trial . The active treatment group receive pravastatin 40 mg/day 6 month vitamin E 300 mg/day add another 6 month homocysteine-lowering therapy ( folic acid 5 mg/day , pyridoxine 100 mg , vitamin B-12 1 mg/day ) . The placebo group receive matching placebo onset , 6 12 month later . Blood pressure group manage accord standard protocol achieve blood pressure &lt; 140/90 mmHg . Patients follow two year . Measurements common carotid artery intima-media thickness ( CCA-IMT ) brachial artery endothelium-dependent , flow-mediated dilatation ( BA-FMD ) perform randomisation 6 , 12 18 month . Plasma oxidize LDL ( oxLDL ) plasma malondialdehyde ( MDA ) measure marker oxidative stress randomisation 6 , 12 , 18 24 month . We use generalize estimate equation ( GEE ) data analysis .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<criteria>chronic kidney disease ( clearence 1570ml/min ) diabetes mellitus ( ADA criterion ) , active vasculitis , nephrotic syndrome ( &gt; 3g protein/24h urine ) , renal transplantation , fast total cholesterol &gt; 7 mmol/L , cholesterollowering therapy within three month prior inclusion know ischaemic coronary , cerebrovascular peripheral arterial disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Kidney , Antioxidants , Statin , Carotid IMT</keyword>
</DOC>